Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Tuberculosis
Interventions
DRUG

Rifampicin in higher doses

Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)

Trial Locations (1)

P.O. box 12

Kibong'oto National Tuberculosis Hospital, Sanya Juu

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

collaborator

Sanofi

INDUSTRY

collaborator

Kilimanjaro Christian Medical Centre, Tanzania

OTHER

collaborator

Kibong'oto National Tuberculosis Hospital, Sanya Juu, Tanzania

UNKNOWN

collaborator

University Centre for Chronic Diseases Dekkerswald, Groesbeek, The Netherlands

UNKNOWN

collaborator

National Institute for Public Health and the Environment (RIVM)

OTHER_GOV

lead

Radboud University Medical Center

OTHER